BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
BioRestorative Therapies, a Nasdaq-listed regenerative medicine company, will present new Phase 2 clinical trial safety and efficacy data on its lead stem cell therapy candidate (BRTX-100) for chronic lumbar disc disease at the ISCT 2026 conference. The company will also showcase preclinical data on its therapeutic and BioCosmeceutical exosome plat…